Premium
Successful treatment of T‐γ lymphoproliferative disease with human‐recombinant granulocyte colony stimulating factor
Author(s) -
Lang David F.,
Rosenfeld C. S.,
Diamond H. S.,
Shadduck R. K.,
Zeigler Z. R.
Publication year - 1992
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830400115
Subject(s) - granulopoiesis , granulocyte colony stimulating factor , immunology , cd8 , eosinophil , medicine , granulocyte , bone marrow , cd3 , cytotoxic t cell , t cell , t lymphocyte , biology , stem cell , chemotherapy , haematopoiesis , immune system , in vitro , biochemistry , genetics , asthma
A trial of recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) was attempted in a male with agranulocytosis, infection, and T‐gamma lymphoproliferative disease (T‐γ‐LPD). During five days of rhG‐CSF (960 μg/day), the absolute neutrophil count (ANC) increased from 0.0 to 4.5 K/μI. There were no changes in eosinophil or lymphocyte counts. In addition, there was no toxicity. Bone marrow cytotoxic/suppressor cells (CD57+/CD8+) were elevated (21.9%) before and decreased to 10.6% (normal < 12%) following rhG‐CSF. By contrast, there was no change in activated T cells (CD3+DR+) or T cell gene rearrangements. These findings suggest rhG‐CSF can improve granulopoiesis in T‐γ‐LPD, possibly by altering T‐cell mediated marrow suppression. © 1992 Wiley‐Liss, Inc.